Hosting Organization



  • Information Research Center of International Talent, SAFEA


  • China Council for the Promotion of International Trade Dalian Sub-Council


  • Dalian Association for International Exchange of Personnal

Operating Organization



  • BIT Congress Inc.

Concurrent
Penta-conferences

Submission guideline

1. The organizing committee of CloudCon-2012 invites all abstracts within the scope of the meeting. Submitted abstracts will be reviewed by experts and scheduled for either poster or oral presentation during the congress. Irrelevant or poor quality abstracts may be rejected.

2. Abstracts may only be submitted by email to tracy@bitcongress.com. It is advisable to prepare the complete text of your abstract as well as any figures or tables before abstract submission.

3. Abstracts need to written in clear English, taking into account the specifications below (see also sample on the next page):

 

a. Maximum word count abstract title: 20 words.

b. Maximum word count abstract text: 350 words (adjust in case of tables/figures).

c. Abstract topic should be selected during the online submission process from the list of predefined topics to facilitate abstract review and scheduling.

d. A minimum of three specific keywords should be added during online submission for indexing of the abstract. Specific keywords are: name(s) of drug(s) investigated, molecular target molecule(s), disease(s) studied, biochemical or biological function(s) studied. Avoid the use of non-specific keywords, such as: angiogenesis, cell death, cancer, tumor, drug development, drug therapy. The Organizing Committee of CloudCon-2012 reserves the rights to delete, edit, or add keywords to achieve uniformity throughout abstract publications.

e. Use International Nonproprietary Names (INN) or research codes to identify drugs throughout the abstract. Proprietary names may be used in the abstract text, not the abstract title; the first time the drug is mentioned there (put proprietary names between brackets).

f. The identity of a new, previously unpublished drug substance needs to be disclosed in the abstract, either by providing its structural formula or its full chemical name.

4. Abstracts will be published exactly as submitted. No editing of abstract texts will be done. However, failure to comply with the above guidelines may be corrected by the meeting organizers.

5. After submission abstracts can no longer be changed by the authors. Should minor changes be necessary after submission, the author should notify Ms. Tracy Liu by email at tracy@bitcongress.com, describing exactly the nature of the change to be made. The CloudCon-2012 organizers will then implement the change. If major changes are required the author should submit a revised abstract as an entirely new abstract and send a request to tracy@bitcongress.com to delete the original abstract. The addition of a co-author constitutes a major change.

6. After completion of the abstract review, the submitting author will receive scheduling information via email. Abstracts cannot be withdrawn after receipt of the scheduling information by the submitting author. The presenting author must be registered as a participant of CloudCon-2012 for final scheduling and publication of the abstract.

7. Accepted abstracts will be published in the Congress Proceedings. The authors of the submitted abstracts are responsible for any Intellectual Property issues concerning the abstracts on their own. The organizing committee of CloudCon-2012 reserves the right to use submitted abstracts for conference purposes.